Natalizumab Misses Endpoint in Secondary Progressive MSNatalizumab Misses Endpoint in Secondary Progressive MS
In the ASCEND trial, treatment did not delay disease progression, the primary endpoint, although there was a benefit on upper-extremity function. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 26, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Rituximab outperforms fingolimod after natalizumab switch
Rituximab is more effective and better tolerated than fingolimod for patients with multiple sclerosis needing to switch from natalizumab due to JC-virus antibody positivity, research suggests. (Source: MedWire News)
Source: MedWire News - April 26, 2016 Category: Consumer Health News Tags: Multiple sclerosis Source Type: news
Tysabri No Help in SPMS
(MedPage Today) -- Drug didnt reduce disability progression but may benefit upper limb function (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 22, 2016 Category: Primary Care Source Type: news
Rituximab is superior to fingolimod for certain patients with multiple sclerosis
A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab. The study included patients infected with JC virus, which is present in approximately 50% of the general population. While the virus generally causes no problems under normal circumstances, it can cause progressive multifocal leukoencephalopathy (PML), a serious demyelinating disease of the brain, in patients with immune deficiencies due to disease or immunosuppressant drugs. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 21, 2016 Category: Science Source Type: news
Rituximab bests fingolimod in MS patients switching from natalizumab
For patients with relapsing-remitting multiple sclerosis (RRMS) switching to other therapies due to positive JC virus serology, treatment with rituximab resulted in a lower rate of clinical relapse... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 4, 2016 Category: Neurology Source Type: news
What Genetics are Associated with Multiple Sclerosis?
Discussion
Multiple sclerosis (MS) is “a chronic degenerative, often episodic disease of the central nervous system marked by patchy destruction of the myelin that surrounds and insulates nerve fibers, usually appearing in young adulthood and manifested by one or more mild to severe neural and muscular impairments, as spastic weakness in one or more limbs, local sensory losses, bladder dysfunction, or visual disturbances.”
It is a chronic disease and therefore symptoms must occur more than once. The first episode is called an acute demyelinating attack. Fifteen to forty-five percent of children with their first...
Source: PediatricEducation.org - April 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Could MS Drug Have a Role in Acute Stroke?Could MS Drug Have a Role in Acute Stroke?
A new study looking at natalizumab to treat stroke showed no effect on the primary endpoint of infarct volume growth, but there was a hint of some clinical benefit. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 7, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
No Benefit for Natalizumab Within 9 Hours of Stroke (CME/CE)
(MedPage Today) -- Early data found no benefit on MRI or NIHSS scores for potent monoclonal antibody (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 19, 2016 Category: Cardiology Source Type: news
New EMA Advice for PML Prevention With Tysabri in MSNew EMA Advice for PML Prevention With Tysabri in MS
The European Medicines Agency has released new recommendations on PML prevention with natalizumab in multiple sclerosis. News Alerts (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Natalizumab Ups JCV Seroconversion, Antibody Index in MSNatalizumab Ups JCV Seroconversion, Antibody Index in MS
New data shed some light on the mechanism behind the PML risk with natalizumab and emphasize the need for regular JC virus testing, researchers say. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 30, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Stratification of Natalizumab-Associated PML RiskStratification of Natalizumab-Associated PML Risk
This consensus paper presents a practical algorithm which can be used to stratify patients with MS according to their risk of developing PML during treatment with natalizumab. Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 28, 2016 Category: Pathology Tags: Neurology & Neurosurgery Journal Article Source Type: news
MS Drug Tied to Higher Risk for Brain Virus
Patients taking Tysabri were more prone to show signs of exposure to JCV, which can cause a brain disease (Source: WebMD Health)
Source: WebMD Health - January 27, 2016 Category: Consumer Health News Source Type: news
MS Drug Tied to Higher Risk for Potentially Deadly Brain Virus
Patients taking Tysabri were more prone to show signs of exposure to JCV, which can cause a brain disease
Source: HealthDay
Related MedlinePlus Page: Multiple Sclerosis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - January 27, 2016 Category: Consumer Health News Source Type: news
More Tysabri Patients Turn Positive for JC Virus Antibodies (CME/CE)
(MedPage Today) -- Seroconversion rates on treatment much higher than expected (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 27, 2016 Category: Neurology Source Type: news
